Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Lupin Ltd.
Change Company   
BSE Code 500257
ISIN Demat INE326A01037
Book Value 576.33
NSE Code LUPIN
Dividend Yield % 0.62
Market Cap 889346.72
P/E 17.06
EPS 114.11
Face Value 2  
06-Sep-2025 USFDA concludes PAI at Lupin’s Aurangabad facility
06-Sep-2025 Lupin informs about disclosure
03-Sep-2025 Lupin gets USFDA’s nod for Risperidone injectable
29-Aug-2025 Lupin informs about updates
20-Aug-2025 Lupin launches Bosentan Tablets for Oral Suspensi...
20-Aug-2025 Lupin informs about press release
12-Aug-2025 Lupin partners with Sandoz Group AG
12-Aug-2025 Lupin rises on partnering with Sandoz Group AG
11-Aug-2025 Lupin launches Glucagon for Injection USP, 1mg/vi...
06-Aug-2025 Lupin reports 52% rise in Q1 consolidated net pro...
06-Aug-2025 Lupin informs about investor presentation
06-Aug-2025 Lupin declines despite reporting 52% rise in Q1 c...
01-Aug-2025 Clarification sought from Lupin Ltd
24-Jul-2025 Lupin gets USFDA’s nod for Liraglutide and Glucag...
24-Jul-2025 Lupin informs about press release
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.